Dr. Casey Moure, a recent graduate of the PhD program in Pathology is happy to share his good news. His graduate research got the cover of Molecular Cancer Research and a research highlight!
Modeling Loss of IDH1 R132H by CRISPR-Cas9
IDH1 hotspot mutations are likely early events in gliomagenesis; however, they can be lost in treated secondary glioblastomas. The cover depicts the DNA helix containing CpG island methylation as bright white foci. Though IDH1 mutations are thought to drive a CpG methylation-high phenotype in glioma, Moure and colleagues found that many methylated foci throughout the genome were retained even after CRISPR/Cas9-mediated knockout of the IDH1 mutant allele.
These findings show that loss of the IDH1 mutation in malignant glioma cells leads to a pattern of DNA methylation alterations, and shows plausibility of IDH1 mutation loss being causally related to the gain of a G-CIMP-low–like phenotype.
(Cover illustration by Samantha Moure)
Check it out: https://mcr.aacrjournals.org/content/17/10.cover-expansion.